Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1

被引：0

作者：

Locke, Frederick ^{[1
]}

Bartlett, Nancy ^{[2
,3
]}

Jacobson, Caron ^{[4
]}

Oluwole, Olalekan ^{[5
]}

Munoz, Javier ^{[6
]}

Lekakis, Lazaros ^{[7
]}

Topp, Max ^{[8
]}

Avivi, Irit ^{[9
]}

Kim, Jenny ^{[10
]}

Chu, Rong ^{[10
]}

Zheng, Lianqing ^{[10
]}

Rossi, John ^{[10
]}

Bot, Adrian ^{[10
]}

Neelapu, Sattva ^{[11
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO 14263 USA

[3] Washington Univ, Siteman Canc Ctr, St Louis, MO 14263 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[7] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[8] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[9] Sourasky Med Ctr, Tel Aviv, Israel

[10] Kite, Santa Monica, CA USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2020年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-25

引用

页码：S21 / S22

页数：2

共 50 条

[1] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick L.
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
[2] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, F. L.
Bartlett, N. L.
Jacobson, C. A.
Oluwole, O. O.
Munoz, J.
Lekakis, L. J.
Topp, M. S.
Avivi, I
Kim, J. J.
Chu, R.
Zheng, L.
Rossi, J. M.
Bot, A.
Neelapu, S. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
[3] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
Neelapu, S. S.
Ghobadi, A.
Jacobson, C. A.
Miklos, D. B.
Lekakis, L. J.
Oluwole, O. O.
Lin, Y.
Braunschweig, I.
Hill, B. T.
Timmerman, J. M.
Deol, A.
Reagan, P. M.
Stiff, P.
Flinn, I. W.
Farooq, U.
Goy, A.
McSweeney, P. A.
Munoz, J.
Siddiqi, T.
Chavez, J. C.
Herrera, A. F.
Xue, A.
Jiang, Y.
Bot, A.
Rossi, J. M.
Kim, J. J.
Go, W. Y.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
[4] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
Locke, Frederick Lundry
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Axicabtagene Ciloleucel (Axi-cel) in Patients With Refractory Large B Cell Lymphoma (NHL): Long-term Follow-up of ZUMA-1
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J. M.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J. S.
Go, W.
Neelapu, S. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 25 - 25
[6] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianging
Rossi, John M.
Locke, Frederick L.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
[7] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van Den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232
[9] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
[10] Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →